The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection

Nicholas I Paton,1,2* Wolfgang Stöhr,1 Lars Oddershede,3 Alejandro Arenas-Pinto,1 Simon Walker,4 Mark Sculpher4 and David T Dunn1 on behalf of the PIVOT trial team†

1Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London, London, UK
2Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3Danish Centre for Healthcare Improvements, Faculty of Social Sciences and Faculty of Health Sciences, Aalborg University, Aalborg, Denmark
4Centre for Health Economics, University of York, York, UK

*Corresponding author
†Members of the PIVOT trial team are listed in the Acknowledgements

Declared competing interests of authors: none

Published March 2016
DOI: 10.3310/hta20210

Scientific summary

The PIVOT trial
Health Technology Assessment 2016; Vol. 20: No. 21
DOI: 10.3310/hta20210

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Standard-of-care antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection uses a combination of drugs, an approach until now considered essential to minimise treatment failure and development of drug resistance. The 2013 British HIV Association (BHIVA) treatment guidelines recommend that an initial treatment regimen should contain two nucleoside reverse transcriptase inhibitors (NRTIs) together with a non-NRTI (NNRTI) drug (efavirenz), a ritonavir-boosted protease inhibitor (PI) [atazanavir or darunavir (DRV)] or an integrase strand-transfer inhibitor (raltegravir). In practice, the most commonly used third drug (on the backbone of two NRTIs) prescribed in the UK has been efavirenz.

Protease inhibitors have very high antiviral activity, have the highest genetic barrier to resistance of all HIV drugs and are the only drugs that act at multiple steps of the HIV lifecycle, thus giving them the potential to be used alone as monotherapy. A randomised controlled trial that examined the use of PI monotherapy in treatment-naive patients showed clearly inferior performance with the generation of substantial drug resistance. However, several other trials in which patients switched to PI monotherapy after achieving full viral load (VL) suppression have produced more encouraging results, in some cases demonstrating non-inferiority compared with standard-of-care (for a primary outcome of short-term VL suppression). However, these trials have used a single protocol-specified PI, lopinavir/ritonavir or DRV/ritonavir, usually mandated for both the monotherapy and the standard-of-care group (thus not resembling standard practice in the UK). Furthermore, the trials have been based on a primary end point of short-term VL suppression (usually at 48 weeks), whereas it is the preservation of adequate future treatment options and the minimisation of toxicity that really matter in long-term HIV care. Although data supporting longer-term meaningful outcomes are limited, PI monotherapy is being increasingly used in clinical practice in the UK and in some European countries.

Objective

To compare the effectiveness, toxicity profile and cost-effectiveness of PI monotherapy with those of standard-of-care triple therapy in a pragmatic long-term clinical trial based in routine clinical care.

Design

Open-label, parallel-group, randomised controlled trial.

Setting

Forty-three HIV clinical centres in the UK NHS with wide geographical representation and including diverse patient populations (14 centres in London, 29 outside London).
Participants

The trial enrolled HIV-positive adults aged > 18 years who had been on ART consisting of two NRTIs and one NNRTI or a PI for at least 24 weeks with no change in the previous 12 weeks and who had a VL of < 50 copies/ml at, and for at least 24 weeks before, screening. The main exclusion criteria were known major PI resistance mutation(s) on previous resistance testing; previous ART change for unsatisfactory virological response; concomitant medication with PI interactions; and central nervous system disease, cardiovascular disease or diabetes.

Interventions

Participants were randomised to maintain ongoing triple therapy (OT) or switch to a strategy of physician-selected ritonavir-boosted PI monotherapy (PI-mono) with prompt return to combination therapy (reintroduction of NRTIs, switch of PI to NNRTI discretionary) in the event of VL rebound (defined as three consecutive tests at > 50 copies/ml, including one repeat on the first sample if available). VL was monitored every 12 weeks.

Protease inhibitor substitution was allowed for toxicity or convenience.

Main outcome measures

The primary outcome was loss of future drug options, defined as new intermediate-/high-level resistance to one or more drugs to which the patient’s virus was considered to be sensitive at trial entry (non-inferiority comparison, 10% margin). The primary analysis included all resistance mutations detected, whereas a predefined sensitivity analysis excluded resistance mutations that were detected to classes of drugs that the patient was not receiving during the trial (and which likely were archived mutations). Secondary outcomes included confirmed VL rebound, serious drug- or disease-related complications, total grade 3 or 4 adverse events (AEs), neurocognitive function change (using a standardised test battery assessing five neurocognitive domains), cluster of differentiation 4 (CD4) cell count change, change in health-related quality of life, cardiovascular risk change, health-care costs and health economic analysis.

Results

In total, 587 participants were randomised (77% male, 68% white) to OT (n = 291) or PI-mono (n = 296) and followed for a median of 44 months, of whom 2.7% withdrew/were lost to follow-up. One or more episodes of confirmed VL rebound were observed in eight patients (Kaplan–Meier estimate 3.2%) in the OT group and 95 patients (35.0%) in the PI-mono group [absolute risk difference 31.8%, 95% confidence interval (CI) 24.6% to 39.0%; p < 0.001]. PI-mono patients who changed to combination ART after VL rebound all resuppressed (median 3.5 weeks). The proportions of participants with loss of a future drug option at 3 years were 0.7% in the OT group and 2.1% in the PI-mono group [difference 1.4% (95% CI –0.4% to 3.4%); non-inferiority demonstrated]. In the prespecified sensitivity analysis, in which mutations that were likely archived were excluded, the proportions of patients with loss of a future drug option at the end of trial follow-up were 1.5% in the OT group and 1.0% in the PI-mono group [difference –0.4% (95% CI –2.1% to 1.4%); non-inferiority also demonstrated]. Only one participant in the PI-mono group developed resistance to the PI that they were taking: a participant taking atazanavir monotherapy who developed the I50L mutation, predicted to confer high-level resistance to atazanavir.
There were no significant differences in serious drug- or disease-related complications between the groups. Although there were more deaths in the PI-mono group (six vs. one), these were of diverse aetiology, often with clear non-HIV-related risk factors present, and the numerical difference was not statistically significant. The numbers of serious adverse events and clinical grade 3 and 4 AEs did not differ between the groups, but there were fewer total grade 3 or 4 AEs in the PI-mono group, the difference reflecting fewer laboratory events. Fewer patients in the PI-mono group experienced an estimated glomerular filtration rate below 60 ml/minute/1.73 m² during follow-up (10% OT group vs. 5% PI-mono group; difference –4.6%, 95% CI –8.8% to –0.4%; p = 0.033). There were no differences between the groups in the proportions of patients with symptomatic peripheral neuropathy, facial lipoatrophy or abdominal fat accumulation or in the summary scores for neurocognitive function, cardiovascular disease risk or quality of life or in the mean CD4 cell count change.

Overall, the PI-mono strategy was shown to be cost-effective compared with OT under most scenarios explored. The PI-mono strategy was cost saving because of large savings in ART drug costs while being no less effective in terms of quality-adjusted life-years in the within-trial analysis and only marginally less effective with modelling.

**Conclusions**

Protease inhibitor monotherapy, with regular VL monitoring and prompt reintroduction of combination therapy for VL rebound, was non-inferior to combination therapy in preserving future treatment options and is an acceptable and cost-effective alternative for long-term management of HIV infection.

**Trial registration**

This trial is registered as ISRCTN04857074.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 5.027

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 06/403/90. The contractual start date was in July 2008. The draft report began editorial review in August 2014 and was accepted for publication in December 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Paton et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK
Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Peter Davidson  Director of NETSCC, HTA, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK
Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk